A Phase 1/2 randomized, placebo-controlled study evaluating the safety, tolerability and efficacy of AKCEA-ANGPTL3-LRx designed to lower ANGPTL3 levels

Trial Profile

A Phase 1/2 randomized, placebo-controlled study evaluating the safety, tolerability and efficacy of AKCEA-ANGPTL3-LRx designed to lower ANGPTL3 levels

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Jun 2017

At a glance

  • Drugs IONIS ANGPTL3 LRx (Primary)
  • Indications Hyperlipoproteinaemia type IIa
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Jun 2017 New trial record
    • 25 May 2017 Results from this trial have been published in The New England Journal of Medicine, according to an Akcea Therapeutics media release.
    • 25 May 2017 Results published in an Akcea Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top